The effect of nicorandil in patients with cardiac syndrome X
A meta-analysis of randomized controlled trials
Qiulei Jia, PhD, Shuqing Shi, PhD, Guozhen Yuan, PhD, Jingjing Shi, PhD, Shuai Shi, PhD, Yi Wei, PhD, Yuanhui Hu, PhD

Abstract
Background: The prevalence of cardiac syndrome X (CSX) is considerable. Some patients show recurrent angina attacks and have a poor prognosis. However, the knowledge of CSX pathophysiological mechanism is still limited, and the treatment fails to achieve a satisfactory suppression of symptoms. Nicorandil has a beneficial effect on improving coronary microvascular dysfunction (CMD). This study aims to evaluate the clinical effects and safety of nicorandil on CSX patients.

Methods: The Cochrane Library, PubMed, EMBASE, ClinicalTrials.gov and 4 Chinese databases were searched to identify relevant studies. The Cochrane “Risk of bias” tool was used to assess the methodological quality of eligible studies. Meta-analysis was performed by RevMan 5.3 software. The Eggers test and meta-regression were performed by software Stata 14.0. Quality of evidence was assessed using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach.

Results: Twenty four randomized controlled trials (RCTs) involving 2323 patients were included. Most of the included studies were classified as having an unclear risk of bias because of poor reported methodology. The main outcomes are angina symptoms improvement, resting electrocardiogram (ECG) improvement, treadmill test result, and endothelial function. Meta-analysis showed that nicorandil had some benefit on improving angina symptoms (RR 1.24, 95% CI 1.19 to 1.29, I² = 20%, P < .00001), resting ECG (RR = 1.24, 95% IC: 1.15 to 1.33, I² = 0%, P < .00001), and prolonged the time to 1 mm ST-segment depression in treadmill test result (WMD = 38.41, 95% IC: 18.46 to 58.36, I² = 0%, P = .0002). Besides, nicorandil could reduce the level of endothelin-1 (ET-1) (SMD = -2.22, 95% IC: -2.61 to -1.83, I² = 77%, P < .00001) and increase the level of nitric oxide (NO) (WMD = 27.45, 95% IC: 125.65 to 29.24, I² = 81%, P < .00001). No serious adverse drug event was reported. The Eggers test showed that significant statistical publication bias was detected (Eggers test P = 0.00). The quality of evidence ranged from very low to low.

Conclusions: Nicorandil shows the potential of improving angina symptoms, ECG, and endothelial dysfunction in patients with CSX. However, there is insufficient evidence for the clinical benefits of nicorandil due to the very low-quality evidence.

Abbreviations: ADEs/ADRs = adverse drug events/reactions, CAD = coronary artery disease, CFR = coronary flow reserve, CI = confidence interval, CMD = coronary microvascular dysfunction, CSX = cardiac syndrome X, ECG = electrocardiogram, ET-1 = endothelin-1, GRADE = Grading of Recommendations Assessment, Development and Evaluation, IMR = index of microcirculatory resistance, ITT = intention-to-treat, MVA = microvascular angina, NO = nitric oxide, RCTs = randomized controlled trials, RR = relative risk, SMD = standardized mean differences, STEMI = ST-segment elevation myocardial infarction, WMD = weighted mean differences.

Keywords: cardiac syndrome X, meta-analysis, nicorandil, randomized controlled trials, systematic review

Editor: Leonardo Roever.
The authors received no funding for this work.
The authors report no conflicts of interest.
The datasets generated during and/or analyzed during the current study are publicly available.

* Correspondence: Yuanhui Hu, Department of cardiovascular, Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China (e-mail: huyiuhui59@163.com).

Copyright © 2020 the Author(s). Published by Wolters Kluwer Health, Inc.
This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to cite this article: Jia Q, Shi S, Yuan G, Shi J, Shi S, Wei Y, Hu Y. The effect of nicorandil in patients with cardiac syndrome X: A meta-analysis of randomized controlled trials. Medicine 2020;99:37(e22167).

Received: 21 March 2020 / Received in final form: 22 July 2020 / Accepted: 27 July 2020
http://dx.doi.org/10.1097/MD.0000000000022167

1
1. Introduction
Cardiac syndrome X (CSX) is usually described as patients with effort-induced symptoms similar to those observed in patients with angina triggered by obstructive coronary artery disease (CAD), poor, or slow response to nitroglycerin, objective evidence of myocardial ischemia including the abnormal electrocardiogram (EKG) and/or stress test results, and completely normal or near-normal coronary arteriograms. No cardiac or systemic diseases should be detectable in these patients.[1,4] The symptom of CSX is regarded as microvascular angina (MVA).[12]

Data from the National Cardiovascular Data Registries CathPCI Registry showed that nearly 60% of 661,063 patients undergoing elective coronary angiography had normal coronary arteries or non-obstructive CAD (stenoses <50%).[3] Coronary microvascular dysfunction (CMD) is typically the mechanism underlying CSX, which refers to impaired vasodilatation and/or increased sensitivity to vasoconstriction in the small resistance coronary arteries.[1,4] Another study certified two-thirds of patients presenting with chest pain in the absence of obstructive CAD showed evidence of microvascular dysfunction.[5]

Previous studies have suggested that the prognosis of CSX patients with the rate of major cardiovascular events is similar to the general population.[6,7] However, in recent years, some studies have demonstrated that coronary microvascular dysfunction is a predictor of future cardiovascular events.[8,9] Patients with stable angina and normal coronary arteries increase the risk of major adverse cardiovascular events, including cardiovascular death, myocardial infarction, stroke or heart failure, and all-cause mortality.[10] Left ventricular longitudinal myocardial systolic function detected by speckle tracking echocardiography was significantly impaired in CSX patients,[11] which is similar to STEMI.[12] Also, some patients show angina attacks more frequent, prolonged, poorly responsive to medical management, depression and psychiatric disturbances, and the quality of their life is severely affected.[13] On the other hand, the worsening of anginal symptoms results in angiography and repeated hospital admissions, imposing a substantial financial burden on health services.[1,14]

The management of patients with CSX is similar to obstructive epicardial coronary artery disease, but also different. Lifestyle modifications, cigarette quitting, blood pressure control, and cardiac rehabilitation are recommended to CSX patients.[15,16] As for pharmacological treatment, the classical antianginal medications are widely used to ameliorate clinical symptoms, including angina, non-dihydropyridine calcium-antagonist drugs, and nitrates. Nitrate are appropriate for patients with increased adrenergic tone. However, nitrate blockers used in patients with microvascular or epicardial spasm may lead to coronary vasoconstriction. Calcium channel blockers are recommended as the initial option for vasospastic angina,[17] while they have no effect on improving microvascular dysfunction.[18] Nitrates seem to be less effective on coronary microvascular disease due to its poor dilator effect on small resistance vessels.[19] Nevertheless, the treatments above are not always based on the pathogenesis, and curative effect is not satisfactory. Thus, seeking for alternative therapies is indispensable.

Nicoland, a potassium ATP channel opener with nitrate-like actions, recommended as a second-line treatment for stable angina by The European Society of Cardiology.[20] Causes epicardial coronary vasodilatation similar to nitrates, as well as dilates coronary microvessels.[21] As its antianginal mechanisms correspond to the pathophysiology of coronary microvascular disease to some extent, nicorandil has been proposed as the first-choice drug for primary stable MVA in China.[22] Previously clinical trials with small sample size showed nicorandil could improve symptoms in CSX patients.[23,24] We conducted a meta-analysis to comprehensively evaluate the clinical curative effect and safety of nicorandil for CSX, providing more therapeutic options for patients.

2. Methods
This systematic review was carried out and reported following Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA)[25] and A Measurement Tool for the “Assessment of Multiple Systematic Reviews” (AMSTAR).[26]

2.1. Search strategy
A comprehensive search strategy was carried out including searching Pubmed (1950 to March 2020), EMBASE (1974 to March 2020), The Cochrane Library (1996 to March 2020), ClinicalTrials.gov (from inception to March 2020), China Knowledge Resource Integrated Database(CNKI)(1979 to March 2020), Chinese Science and Technique Journals Database(VIP)(1989 to March 2020), Wan Fang Database(Wan Fang)(1990 to March 2020) and the Chinese Biomedical Database(CBM)(1990 to March 2020). The following medical subject heading terms were used: “nicorandil”, “microvascular angina” and “cardiac syndrome X”.

2.2. Study selection
Studies meeting the following criteria were included:
1. Randomized controlled trials (RCTs);
2. Participants diagnosed as CSX by the criteria listed in Angina pectoris and normal coronary arteries: cardiac syndrome X.[2]
3. Participants with acute myocardial infarction, heart failure, hepatic failure, and renal failure were excluded;
4. The intervention was nicorandil with or without routine treatment vs controls including placebo, routine treatment, or positive medicine control. Routine treatment includes aspirin, β-blockers, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, calcium channel blockers, statins;
5. Primary outcomes including angina improvement, the resting ECG improvement, treadmill test results, readmission rate, and coronary microvascular function tests, such as coronary flow reserve (CFR) or index of microcirculatory resistance (IMR); secondary outcomes including endothelial function, and any adverse drug events/reactions (ADEs/ADRs).

There were no restrictions on the publication type and characteristics of participants. Duplicate publications reporting the same groups of participants were excluded.

The titles, abstracts, and keywords of records retrieved were scanned to determine whether to be assessed further. Full articles were retrieved for further assessment if the information met the inclusion criteria. Any disagreement between reviewers was resolved by discussion or consulting a third party.

2.3. Data extraction and management
Data concerning details of the study population, intervention and outcomes were extracted independently by 2 reviewers. For
binary outcomes, the number of events and total number in each group was extracted. For continuous outcomes, mean, standard deviation and sample size of each group were extracted. The data extraction form included the following items:

1. General information: title, authors, and year of publication.
2. Trial characteristics: study design, method of randomization, allocation concealment, blinding.
3. Patients: number in treatment and control groups, age, diagnostic criteria, withdrawals/losses to follow-up (reasons/description), subgroups.
4. Intervention: intervention (dose, course of treatment, and frequency), comparison intervention (dose, course of treatment, and frequency).
5. Outcomes: outcomes specified above. The study was not conducted directly on patients, therefore ethical approval was not necessary.

2.4. Quality assessment

The methodological quality of trials was assessed independently using criteria from the Cochrane Handbook for Systematic Review of Interventions, Version 5.1.0.\textsuperscript{[27]} Seven domains are considered such as sequence generation (selection bias), allocation concealment (selection bias), blinding of participants and personnel (performance bias), blinding of outcome assessment (detection bias), incomplete outcome data (attrition bias), selective outcome reporting (reporting bias), and other bias. Three levels of “low risk”, “high risk”, or “unclear risk” were the quality appraisal category. Any disagreements were resolved by mutual consensus.

2.5. Data synthesis

Revman 5.3 software provided by the Cochrane Collaboration was used for data analyses. The model used to pool the data
### Table 1
Characteristics of included studies.

| Study ID   | Study type | Case/Control | Mean age/sex | Gender | Use method of microneedle | Combined with treatment | Control group | Washout period / (week) | Duration | Outcomes |
|------------|------------|--------------|--------------|--------|---------------------------|-------------------------|--------------|-------------------------|----------|----------|
| Chen, 1997 | crossover design | 13/13 | T:57.1±6.2, C:51.0±3.1 | T:11/13, C:10/13 | 5 mg tid po for 2 weeks | none | Placebo | 2 | 6 weeks | 1 3 4 10 |
| Oraby, 2011 | crossover design | 26/26 | T:57.1±6.2, C:51.0±3.1 | T:11/13, C:10/13 | 10 mg bid po for the first 2 weeks | none | Isosorbide dinitrate (20 mg bid for the first 2 weeks followed by 40 mg bid for the next 2 weeks) | 1 9 weeks | 1 3 4 10 |
| Chen, 2014 | parallel test | 50/50 | T:64.5±4.8, C:60.3±4.2 | T:28/22, C:26/24 | 5 mg tid po | RT | RT | - 12 weeks | 1 2 4 10 |
| Chen, 2018 | parallel test | 51/51 | T:34.1±11.7, C:33/28 | T:28/22, C:26/24 | 5 mg tid po | RT | RT | - 8 weeks | 1 3 4 10 |
| Cui, 2016 | parallel test | 40/40 | T:65.8±5.9, C:64/28 | T:26/14, C:24/28 | 5 mg tid po | RT | RT | - 12 weeks | 1 3 4 10 |
| Gao, 2016 | parallel test | 41/40 | T:51.4±11.8, C:51/28 | T:12/29, C:11/27 | 5 mg tid po | RT | RT | - 4 weeks | 1 3 4 10 |
| Han, 2017 | parallel test | 20/20 | T:51.0±8.45, C:51.0±8.48 | T:7/13, C:7/13 | 5 mg tid po | RT | RT | - 8 weeks | 1 3 4 10 |
| He, 2015 | parallel test | 60/60 | T:56.78±4.68, C:56/28 | T:34/26, C:32/24 | 5 mg qd po | RT | RT | - 12 weeks | 1 3 4 10 |
| He, 2017 | parallel test | 64/58 | T:47.0±9.8, C:49/30 | T:19/21, C:18/23 | 5 mg tid po | RT | RT | - 12 weeks | 1 3 4 10 |
| He, 2019 | parallel test | 45/45 | T:51.4±2.6, C:51/28 | T:21/24, C:20/26 | 5 mg tid po | RT | RT | - 4 weeks | 1 3 4 10 |
| Hong, 2019 | parallel test | 60/60 | T:59.67±6.88, C:59/39 | T:36/28, C:34/26 | 5 mg qd po | RT | RT | - 4 weeks | 1 3 4 10 |
| Ji, 2020 | parallel test | 136/138 | T:62.30±7.92, C:61/30 | T:78/58, C:76/58 | 5 mg tid po | RT | RT | - 6 months | 1 3 4 10 |
| Jin, 2016 | parallel test | 60/60 | T:63.75±5.1, C:63/28 | T:34/26, C:32/24 | 5 mg tid po | RT | RT | - 12 weeks | 1 3 4 10 |
| Jin, 2018 | parallel test | 69/69 | T:62.1±8.7, C:61/28 | T:41/28, C:39/26 | 5 mg tid po | RT | Trimegestatine (20 mg tid po+RT) | - 4 weeks | 1 3 4 10 |
| Liu, 2018 | parallel test | 30/30 | T:60.2±3.4, C:60/31 | T:15/15, C:15/15 | 5 mg tid po | RT | RT | - 3 weeks | 1 3 4 10 |
| Lv, 2018 | parallel test | 23/22 | T:NA, C:NA | T:NA, C:NA | 5 mg tid po | RT | RT | - 12 weeks | 1 3 4 10 |
| Quan, 2018 | parallel test | 52/52 | T:56.9±6.0, C:56/28 | T:25/27, C:24/26 | 5 mg tid po | RT | RT | - 4 weeks | 1 3 4 10 |
| Wang, 2018 | parallel test | 32/32 | T:56.7±6.1, C:56/28 | T:25/27, C:24/26 | 5 mg tid po | RT | Trimegestatine (20 mg tid po+RT) | - 8 weeks | 1 3 4 10 |
| Xu, 2019 | parallel test | 75/75 | C:55.4±4.5, C:55/31 | T:15/17, C:15/17 | 5 mg tid po | RT | RT | - 4 weeks | 1 3 4 10 |
| Yan, 2019 | parallel test | 43/43 | T:48.3±3.4, C:48/31 | T:48/32 | 5-10 mg tid po | RT | RT | - 4 weeks | 1 3 4 10 |
| Yin, 2019 | parallel test | 30/30 | T:65.4±6.8, C:65/31 | T:17/17, C:17/17 | 5 mg tid po | RT | Trimegestatine (20 mg tid po+RT) | - 4 weeks | 1 3 4 10 |
| Zhang, 2019 | parallel test | 43/43 | C:63.3±9.7, C:63/28 | T:18/12, C:18/12 | 5 mg tid po | RT | RT | - 4 weeks | 1 3 4 10 |
| Zhou, 2019 | parallel test | 50/50 | C:65.4±6.8, C:65/31 | T:22/28 | 5 mg tid po | RT | Isosorbide dinitrate (10 mg tid po+RT) | - 12 weeks | 1 3 4 10 |

Bid = 2 times/day, C = control group, NA = not acquired, po = oral, Qd = 1 time/day, RT = routine treatment, T = treatment group, Tid = 3 times/day. (1) = angina improvement, (2) = the improvement of resting ECG, (3) = total exercise duration, (4) = time to 1 mm ST-segment depression, (5) = maximum depression of the ST segment at treadmill test, (6) = readministration rate, (7) = coronary flow reserve, (8) = endothelial dysfunction, endothelium -1, (9) = nitric oxide, (10) = adverse events/reactions.

### Table 2
Meta-regression of basic characteristics of RCTs and RRs of angina improvement.

| logRR     | Coef. | Std.Err. | t      | P > | 95% Conf. | Interval |
|-----------|-------|----------|-------|-----|----------|----------|
| Study type | -0.6704 | 0.2747 | -2.44 | .027 | -1.2528 | 0.0879195 |
| Comparison intervention | 0.0090 | 0.0304 | -0.30 | .768 | -0.3539 | 0.7024 |
| Duration of treatment | -0.0090 | 0.0200 | -0.43 | .670 | -0.3539 | 0.3539 |
| cons      | 1.52825 | 0.548608 | 2.79 | .013 | 0.3665250 | 2.6899740 |

Medicine
depends on the existence and extent of heterogeneity. If the $I^2$ statistics were less than 50%, the heterogeneity could be accepted, and the fixed-effect model was chosen. If the $I^2$ statistics exceeded 50%, the random-effects model was used. When heterogeneity among studies was obvious ($I^2 > 50%$), the sources of heterogeneity would be investigated. For binary outcomes, the pooled relative risk (RR) with 95% confidence interval (CI) was used as the effect measure. For the continuous outcome, weighted mean differences (WMD) or standardized mean differences (SMD) was used as the effect measure, both with 95% confidence intervals (CI). The approach to incorporating cross over trials is to take all measurements from the 2 intervention periods and analyse these as if the trial were a parallel-group trial.[27] Publication bias would be assessed by funnel plot and the Eggers test if the group included more than 10 studies. The Eggers test was performed by software Stata 14.0 (Stata Corp, College Station, Tex).

### 2.6. Subgroup analysis, sensitivity analysis, and meta-regression

Subgroup analysis, sensitivity analysis, and meta-regression analysis were performed to explore potential sources of heterogeneity. Subgroup analysis was also conducted to determine whether there was a different effect of an intervention in different situations. Sensitivity analysis was completed by changing the effect model or removing 1 study at a time to investigate the influence of a single study on the overall pooled estimate. Meta-regression analysis was performed using residual maximum likelihood (REML) with Knapp-Hartung modification by software Stata 14.0.

### 2.7. Quality of evidence assessment

The quality of evidence was assessed using The Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach[28] by which a determination of high, moderate, low, or very low was made for each major outcome.

### 3. Results

In total, 264 records were identified. After duplicates among different databases were removed, 116 records were kept for further assessment. The full texts of 51 remaining records were downloaded for careful assessment. There were 24 trials included in the review. The detailed process of search and identification was shown in Figure 1.

Details of the 24 included studies[24,29–51] are shown in Table 1. Twenty two studies[30–51] included were parallel test, and 2 studies[24,29] were cross over design. Trial duration ranged from 3 weeks to 6 months. The number of participants in the studies ranged from 13 to 274, with a total of 2323 participants included in this review. The average ages of participants ranged from 43 to 64 years old.

One study[24] compared nicorandil with a placebo. One study[29] compared nicorandil with isosorbide dinitrate. One study[49] made a comparison between nicorandil with routine treatment and isosorbide dinitrate with routine treatment. Three studies[40,44,47] compared between nicorandil with routine treatment and trimetazidine with routine treatment. The other studies[30–39,41–43,45,46,48,50,51] compared nicorandil with routine treatment vs routine treatment.

Nicorandil was given by oral administration. The dose of nicorandil varied across studies: 5 mg once a day used in 1 study,[38] 10 mg twice a day for the first 2 weeks, then increasing to 20 mg twice a day for the next 2 weeks used in 1 study,[29] 5 mg 3 times a day used in 21 studies,[24,30–37,39,45,47,48,50,51] 5 to 10 mg 3 times a day used in 1 study.[46]

The patients in 10 studies[34,38,40,41,43,45–48,50] received treatment for less than or equal to 4 weeks, and the patients in 5 studies[24,29,31,35,40] received treatment for 6 to 9 weeks, and the remaining patients in 8 studies[30,32–34,36,37,39,49] received treatment for 12 weeks, the patients in 1 study[51] received treatment for 6 months.

Twenty studies[24,28–34,36,39–41,43–51] reported rate of angina improvement. Six studies[30,32,36,39,41,49] reported the improvement of resting ECG. In regard to treadmill exercise test, 9 studies[24,29,33,40,42,47,48,50,51] reported total exercise duration during. Three studies[24,29,51] reported the time to 1 mm ST-segment depression. Four studies[24,35,42,50] compared maximum depression of the ST-segment at treadmill exercise test. Only 1 study[51] reported the readmission rate. One study reported CFR.[47] Seven studies[30,32,35,36,37,39,46] reported the level of ET-1 and NO.

Fifteen studies[24,29,30,33,34,36,38,40,41,43,45,48–51] observed ADEs/ADRs, thirteen[24,29,30,33,36,38,40,41,43,45,48,49,51] of them reported positive result. The details of the study characteristics were summarized in Table 2.
3.1. Methodological quality

Firstly, the risk of bias in cross-over trials is assessed according to Cochrane Handbook. CSX is a condition that is chronic and relatively stable. The primary outcomes do not include irreversible conditions, that is, death. The carryover effect contains a pharmacological effect and psychological effect. In Chen’s[24] and Oraby’s[29] studies, random, double-blinding, and a washout period between treatment periods may reduce the risk of carryover effect. None of the participants dropped out after the first treatment, and all of them finished the two-stage treatment. Both the cross-over studies adopted two-stage data. But the authors did not offer paired data, and neither of them mentioned the randomization method or allocation concealment. One study[24] reported withdrawal, but the intention-to-treat (ITT) analysis was not mentioned.

All the parallel-group trials[30–51] studies mentioned randomization. However, only 9 studies[30,33,35–37,46,48,50,51] described the allocation sequence being generated from random number tables, and 1 study[39] elaborated by sortition. One study[37] mentioned withdrawal. None mentioned allocation concealment or ITT analysis. Only 1 study[35] mentioned single blinding. We believed all included studies to be free of selective reporting because the same outcomes were described in the methods and reported in the results. In all studies, the characteristics of participants in different treatment groups were similar at baseline (age, sex, the severity of angina). So we considered all included trials to be free of other potential sources of bias (Figs. 2 and 3).

3.2. Publication bias

The funnel plot was slightly asymmetric when pooling 20 trials on the rate of angina symptoms improvement, which indicated some evidence of publication bias (Fig. 4). The Eggers test showed that significant statistical publication bias was detected (Eggers test \( P = .000 \)) (Fig. 5).

3.3. Effects of interventions

3.3.1. Angina symptoms improvement: rate of angina symptoms improvement. Twenty studies[24,29–34,36,39–41,43–51] assessed the rate of angina symptoms improvement. A decrease in the frequency of angina attacks was the measure. Nicorandil has a better effect on improving angina symptoms (RR 1.24, 95% CI 1.19 to 1.29, \( I^2 = 20\% \), \( P < .00001 \), Fig. 6). Subgroup analysis shows the effects of treatment group on improving angina symptoms are better than routine treatment alone[30–34,36,39,41,43,44,46,48,50,51] (RR 1.22, 95% CI 1.16 to 1.28, \( I^2 = 2\% \), \( P < .00001 \), Fig. 7), trimetazidine with routine treatment[40,44,47] (RR 1.20, 95% CI 1.08–1.32, \( I^2 = 0\% \), \( P = .0006 \), Fig. 7), and isosorbide dinitrate group[29,49] (RR 1.48, 95% CI 1.18–1.85, \( I^2 = 62\% \), \( P = .0007 \), Fig. 7). There is only 1 RCT[24] in placebo group, synthesis analysis cannot be performed.

To explore this heterogeneity, we conducted a meta-regression analysis of study type, comparison intervention, and duration of treatment by REML with Knapp-Hartung modification. Tau² was equal to 0.001136 as REML estimates of between-study variance. \( I^2 \) was 0.00% in terms of the proportion of residual variation due to heterogeneity. The adjusted \( R^2 \) value was equal to −45.61%, with the proportion of between-study variance explained. Data from Table 2 shows there was a significant association between study type and the final result (\( P = .027 \), 95% CI −1.25 to −0.087). We divided the studies into 2 subgroups according to study type, and then the subgroup
analysis showed no statistical heterogeneity was found in each subgroup ($P = .59, I^2 = 0\%$; $P = .38, I^2 = 0\%$, Fig. 8).

### 3.3.2. Resting ECG improvement: rate of resting ECG improvement.
Six studies\cite{30, 32, 36, 39, 41, 49} reported the rate of ECG improvement. Improvement of ST-segment depression and T wave inversion was the most common measure. Nicorandil combined with routine treatment has a better effect on improving ECG compared with the control group ($RR = 1.24$, 95% IC: $1.15–1.33$, $I^2 = 0\%$, $P < .00001$, Fig. 9).

### 3.3.3. Treadmill test result: total exercise duration.
Nine studies\cite{24, 29, 35, 40, 42, 47, 48, 50, 51} reported total exercise duration. Available data could be extracted from 8 studies.\cite{24, 35, 40, 42, 47, 48, 50, 51} Because obvious heterogeneity was observed among these studies, a random-effect model was used. The result showed that nicorandil had a better effect on increasing total exercise duration than the control group ($WMD = 44.36$, 95% IC: $23.99–64.73$, $I^2 = 74\%$, $P < .0001$, Fig. 10). We removed the Jin ZF 2016 study, the heterogeneity in the 7 remaining studies is moderate. Meta-analysis of these 7 studies showed the effect of nicorandil on increasing total exercise duration remained ($WMD = 51.98$, 95% IC: $35.85–68.10$, $I^2 = 47\%$, $P < .00001$).

### 3.3.4. Treadmill test result: time to 1mm ST-segment depression.
Three studies\cite{24, 29, 51} reported time to 1mm ST-segment depression, but available data only could be extracted from 2 studies.\cite{24, 51} The result showed that nicorandil had a better effect on prolonging time to 1mm ST-segment depression ($WMD = 38.41$, 95% IC: $18.46–58.36$, $I^2 = 0\%$, $P = .0002$, Fig. 11).

### 3.3.5. Treadmill test result: maximum depression of the ST-segment.
Four studies\cite{24, 35, 42, 50} reported maximum depression of the ST-segment. A random-effect model was applied because of the obvious heterogeneity. The result showed that nicorandil had a better effect on improving the maximum depression of the ST-segment ($WMD = −0.29$, 95% IC: $−0.55$ to $−0.03$, $I^2 = 80\%$, $P = .03$, Fig. 12). When we removed the He 2019 study, there was no evidence of heterogeneity in the remaining studies. However, meta-analysis demonstrated no significant difference between the treatment group and control groups in the maximum depression of the ST-segment ($WMD = −0.12$, 95% IC: $−0.25$ to 0, $I^2 = 0\%$, $P = .05$).

### 3.3.6. Readmission rate.
Only 1 study\cite{51} reported the readmission rate. The rate of readmission in the nicorandil group (22/136) was lower than in the control group (38/138).

### 3.3.7. Coronary microvascular function test: coronary flow reserve.
Only 1 study\cite{47} reported CFR measured by transtho-
ratic Doppler echocardiography. Nicorandil combined with routine treatment had an advantage of increasing CFR than trimetazidine combined with routine treatment (WMD = 0.36, 95% IC: 0.07–0.65, P = .01).

3.3.8. Endothelial function: the level of endothelin-1. Seven studies [30, 32, 33, 36, 37, 39, 46] reported changes in endothelin-1 (ET-1) levels. Statistical heterogeneity was observed, and the units of outcomes varied. Thus, a random-effect model and SMD were used. Pooled results indicated greater effects of nicorandil on reducing ET-1 levels (SMD = –2.22, 95% IC: –2.61 to –1.83, I² = 77%, P < .00001, Fig. 13). When we removed the Yan 2018 study, there was no evidence of heterogeneity in the remaining studies, and meta-analysis showed the effect remained (SMD = –1.99, 95% IC: –2.18 to –1.8, I² = 0%, P < .00001).

3.3.9. Endothelial function: the level of nitric oxide. Seven studies [30, 32, 33, 36, 37, 39, 46] reported changes in nitric oxide (NO) levels. Statistical heterogeneity was observed, thus, a random-effect model was used. Pooled results indicated greater effects of nicorandil on increasing NO levels (WMD = 27.45, 95% IC: 12.56–29.24, I² = 81%, P < .00001, Fig. 14). When we removed the Yan 2018 study, there was no evidence of heterogeneity in the remaining studies, and meta-analysis showed the effect remained (WMD = 28.22, 95% IC: 27.34–29.11, I² = 0%, P < .00001).

3.4. Adverse events/reactions
Among the 24 included studies, 15 studies observed ADEs/ADRs [24, 29, 30, 33, 34, 36, 38, 39, 41, 43, 45, 48–51] reported positive results. Headache, dizziness, and gastrointestinal symptom were the major adverse drug reactions in both treatment group and control group. The details of ADEs/ADRs were summarized in Table 3.

3.5. Quality of evidence assessment
The overall assessment of quality of evidence ranged from very low to low according to GRADE methodology, which was summed up in Table 4.

4. Discussion
4.1. Findings
Angina symptoms improvement, resting ECG improvement, treadmill test result, and endothelial function have become the main outcomes analyzed in this review. The results of our meta-analysis showed that nicorandil had a better effect on improving angina symptoms, decreasing the frequency of angina attack, and improving ST-segment depression and T wave inversion in resting ECG. The treadmill test can be used to evaluate the efficacy of therapy on control of ischemia [20]. The effect of nicorandil on increasing total exercise duration and prolonging time to 1 mm ST-segment depression was better than the control group. However, there was a large heterogeneity between the 2 groups in total exercise duration. We performed a sensitivity analysis by removing 1 study [44] with trimetazidine as comparison intervention and found that the effect of nicorandil on increasing total exercise duration remained. Also, the apparent heterogeneity in the maximum depression of the ST-segment attributed to the baseline levels before treatment. We removed the study [50] whose
maximum ST-segment depression was less than the others, and found heterogeneity disappeared. However, there was no statistically significant difference between the nicorandil group and control group. Therefore, the effect on improving the maximum depression of the ST-segment for nicorandil is not definite. Recurrent angina attacks contribute to repeated multiple diagnostic investigations and hospitalization, which impaired the quality of life. Nicorandil may lower down the rehospitalization rate of patients with CSX, but the result needs more studies to confirm.

The pathogenesis of CSX is attributed to CMD, which is defined as CFR < 2.0 measured by positron emission computed tomography. CFR refers to the ratio of myocardial blood flow during near maximal coronary vasodilatation to baseline myocardial blood flow. Decreased CFR is representative of microvascular dysfunction. Moreover, low CFR has predicted a poor prognosis in patients with and without obstructive CAD. However, only 1 study reported that nicorandil had an advantage of increasing CFR, hence there is insufficient evidence to support the effect of nicorandil on improving CFR. Endothelial dysfunction is the most accepted mechanism leading to CMD, can be defined as an imbalance between vasodilator factors such as NO, prostacyclin, and vasoconstrictor factors such as ET-1, thromboxane A2, prostaglandin H2. Reduced bioavailability of NO influences the migratory and angiogenic of endothelial cells, inducing vessel destruction, microvascular rarefaction, and decreased microvascular density, which may partly explain the coronary microvasculature abnormalities in patients with coronary microvascular disease. The concentration of NO and the NO/ET-1 ratio are decreased in patients with
Our study showed that the ET-1 level was decreased, and the NO level was significantly increased by nicorandil. The sensitivity analysis was further performed for ET-1 with obvious heterogeneity. We removed 1 study with a 4 weeks treatment and found that the effect of nicorandil on reducing the level of ET-1 was not significantly changed. Large heterogeneity also was observed among the studies on NO level. We excluded the study with a 4 weeks treatment and found that the effect of nicorandil on reducing the level of ET-1 was not significantly changed. Large heterogeneity also was
Figure 10. Forest plot of total exercise duration.

Figure 11. Forest plot of time to 1 mm ST-segment depression.

Figure 12. Forest plot of maximum depression of the ST-segment.

Figure 13. Forest plot of ET-1 level. ET-1 = Endothelin-1.
| Study ID | Treatment group dose of nicorandil (/mg/day) | Control group | Duration | ADEs/ADRs | Treatment for ADEs/ADRs |
|----------|---------------------------------------------|---------------|----------|-----------|-------------------------|
| Chen, 1997[25] | 15 | Placebo | 2 weeks | headache in 1 case; Nausea and malaise in 1 case | NA |
| Oraby, 2011[29] | 20 mg for the first 2 weeks up titrated 40 mg for the next 2 weeks | Isosorbide dinitrate | 4 weeks | headache in 6 cases | headache in 18 cases |
| Cen, 2014[30] | 15 | RT | 12 weeks | slight headache and nausea in 1 case | headache, nausea and inappetence in 1 case |
| Cui, 2018[33] | 15 | RT | 12 weeks | nausea in 1 case | nausea in 1 case; vomit in 1 case |
| Gao, 2016[34] | 15 | RT | 12 weeks | slight pain in 2 cases; nausea in 1 case | no adverse reaction |
| He, 2015[36] | 15 | RT | 12 weeks | nausea and vomit in 2 cases; inappetence in 2 cases | |
| He, 2019[50] | 15 | RT | 4 weeks | no adverse reaction | no adverse reaction |
| Hong, 2019[38] | 5 | RT | 4 weeks | Dizziness in 1 case; stomachache in 1 case; palpitation in 1 case | Dizziness in 1 case; stomachache in 1 case; palpitation in 1 case; insomnia in 1 case |
| Ji, 2020[51] | 15 | RT | 6 months | headache and dizziness in 4 cases; nausea and vomit in 4 cases; palpitation and flushed face in 2 cases; inappetence in 2 cases | headache and dizziness in 6 cases; nausea and vomit in 2 cases; palpitation and flushed face in 4 cases; inappetence in 4 cases |
| Jin, 2018[39] | 15 | RT | 12 weeks | headache, nausea and inappetence in 1 case | headache, nausea and inappetence in 1 case |
| Liu, 2018[41] | 15 | RT | 3 weeks | Dizziness in 2 cases; weakness in 1 case; palpitation in 1 case | Dizziness in 3 cases; weakness in 4 cases; palpitation in 4 cases |
| Quan, 2018[43] | 15 | RT | 4 weeks | Dizziness and palpitation in 3 cases | Dizziness and palpitation in 4 cases |
| Xu, 2017[45] | 15 | RT | 4 weeks | Dizziness in 2 cases; stomachache in two cases; palpitation in 1 case; insomnia in 1 case | Dizziness in 4 cases; headache in 2 cases; stomachache in 4 cases; palpitation in 2 cases; insomnia in 2 cases |
| Zhang, 2017[46] | 15 | RT | 4 weeks | Dizziness in 2 cases; headache in 1 case; hypotension in 1 case; palpitation in 1 case | Dizziness in 1 case; hypotension in 1 case; palpitation in 1 case |
| Zhou, 2012[49] | 15 | Isosorbide dinitrate+RT | 12 weeks | no adverse reaction | slight headache and a small drop in blood pressure decreasing in some patients at the beginning of treatment |

Aspirin = angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, beta-blockers, calcium channel blockers, statins, NA = not Acquired, RT = Routine treatment.
Table 4
GRADE evidence profile.

| Outcomes                              | Quality assessment | Number of patients | Effect 95%CIs               | Quality of evidence |
|---------------------------------------|--------------------|--------------------|-----------------------------|---------------------|
|                                       | Risk of bias       | Inconsistency      | Indirectness | Imprecision | Other considerations | Nicorandil | Control | Relative | Absolute |                        |
| Angina improvement                    | very serious*†    | no                 | no           | serious*     | reporting bias   | 893/998  | 721/999 | RR1.24   | (1.19 to 1.29) | more to 209 more | ¬¬¬¬, very low |
|                                       |                    |                    |              |             |                  | (89.5%) | (72.2%) |          |          |                      |
| Resting ECG improvement               | very serious*     | no                 | no           | serious*     | reporting bias   | 278/302  | 225/302 | RR1.24   | (1.15 to 1.33) | more to 246 more | ¬¬¬¬, very low |
|                                       |                    |                    |              |             |                  | (92.1%) | (74.5%) |          |          |                      |
| Total exercise duration               | very serious*†    | very serious†     | no           | serious*     | none             | 379     | 380     | –        | MD 34.36 higher (23.99 to 64.37 higher) | ¬¬¬¬, very low |
|                                       |                    |                    |              |             |                  | (92.1%) | (74.5%) |          |          |                      |
| Time to 1 mm ST segment depression    | very serious*†    | no                 | no           | no          | reporting bias   | 149     | 151     | –        | MD 38.41 higher (18.46 to 58.30 higher) | ¬¬¬¬, very low |
|                                       |                    |                    |              |             |                  | (92.1%) | (74.5%) |          |          |                      |
| Maximum depression of the ST segment at treadmill test | very serious*† | very serious† | no | serious* | reporting bias | 101 | 100 | – | MD 0.29 lower (0.55 to 0.03 higher) | ¬¬¬¬, very low |
|                                       |                    |                    |              |             |                  | (92.1%) | (74.5%) |          |          |                      |
| ET-1                                  | very serious*†    | very serious†     | no           | no          | reporting bias   | 369     | 363     | –        | SMD 2.22 lower (2.61 to 1.83 lower) | ¬¬¬¬, very low |
|                                       |                    |                    |              |             |                  | (92.1%) | (74.5%) |          |          |                      |
| NO                                    | very serious*†    | very serious†     | no           | no          | reporting bias   | 369     | 363     | –        | MD 27.45 higher (25.65 to 29.24 higher) | ¬¬¬¬, very low |
|                                       |                    |                    |              |             |                  | (92.1%) | (74.5%) |          |          |                      |
| Readmission rate                      | very serious*     | no                 | no           | no          | none             | 22/136  | 38/138  | RR0.59   | (0.37 to 0.94) | fewer to 173 fewer | ¬¬¬¬, low |
|                                       |                    |                    |              |             |                  | (16.2%) | (27.3%) |          |          |                      |
| CFR                                   | very serious*     | no                 | no           | no          | none             | 30      | 30      | –        | MD 0.36 higher (0.07 to 0.65 higher) | ¬¬¬¬, low |

* Sequence generation, allocation concealment, blinding of participants and personnel, blinding of outcome assessment are not mentioned.
† ITT analysis was not performed in the trails with withdrawal or drop-out.
‡ I² > 50%
§ The boundaries of the confidence interval are not on the same side of the threshold.

Jia et al. Medicine (2020) 99:37 www.md-journal.com
nicorandil on increasing NO level remained. We can speculate that the effect of nicorandil on ET-1 and NO level is associated with the duration of treatment.

It has been reported that nicorandil could augment CFR in patients with angina pectoris and nearly normal coronary arteriograms. Studies have shown that intracoronary nicorandil ameliorated microvascular dysfunction, which was evaluated with IMR, and improved CFR in patients with STEMI undergoing primary percutaneous coronary intervention. In addition, nicorandil may improve chest pain symptoms, and regulate plasma NO and ET-1 in the coronary slow flow. Nicorandil as a vasodilator exerts effects both as a potassium ATP channel opener and a nitrate. It can dilate the coronary artery microvessels with a diameter of <100 μm, thus reduce coronary arterial resistance, causing an increase in coronary blood flow. It also enhances ischemic preconditioning through the activation of the potassium ATP channel in mitochondrial membranes. Oxidative stress is associated with impaired endothelium. Several pieces of research have reported that there is systemic oxidative stress in cardiac syndrome X patients. Nicorandil decreases xanthine oxidase-generated reactive oxygen species induced by rapamycin. Moreover, it can increase reendothelialization impaired by rapamycin and endothelial nitric oxide synthase expression inhibited by rapamycin.

There is inadequate reporting on ADEs/ADRs in the included trials. Known ADRs of nicorandil mainly were headache, nausea and vomit, dizziness, fever, weakness, ulceration, liver dysfunction, jaundice, thrombophenia. Some ADRs in this review we found were new, for instance, palpitation, stomachache, inappetence, insomnia, hypotension, and so on. They were not serious and relieved by symptomatic treatment. We could not make a clear causal connection judge due to nicorandil or other routine treatments. Some case reports mentioned ulcers induced by nicorandil, including oral, anal, perianal, perivulval, gastrointestinal, colonic, peristomal and skin ulceration, which were not found in these including studies.

Most of the included studies were classified as being low quality, and they were assessed as having an unclear risk of bias with the Cochrane Collaboration “Risk of bias” tool. The sample size calculation was not reported in any study. ITT analysis was not performed in the trials with withdrawal or drop-out. Only 1 study used a placebo as a control treatment. What’s more, no multi-center, large scale RCT was found. All studies are small, with positive findings, and without ITT analysis, resulting in publication bias. Hence, we need more high-quality RCTs to prove the efficacy and safety of nicorandil for CSX patients.

We found out 2 systematic reviews of CSX. One review evaluated the efficacy of traditional Chinese medicine, including Chinese patent drug, decoction, and Chinese medicine injection, compared with conventional treatment for patients with CSX. Another review assessed the efficacy and safety of Tongxinluo Capsule for CSX. Their outcomes were angina symptom improvement, ECG improvement, treadmill test results, and ET-1 level, lacking readmission rate and coronary microvascular function test.

4.2. Implications for practice

There is very low to low-quality evidence from the included studies to suggest that nicorandil is not an effective intervention for patients with CSX. More high-quality studies are required to identify its efficacy and safety. The prescription drug label of nicorandil states that it is used for angina pectoris, but there is no restriction on the type of angina. It is necessary to identify the mechanism of nicorandil for CSX by more experiments and clinical researches.

4.3. Implications for future research

The methodological quality of clinical trials of treatment with nicorandil for CSX needs to be improved. Firstly, methods of random sequence generation and allocation concealment should be described, blinding, and sample size calculation should be applied in the study. Secondly, clinical trial registries should be encouraged to provide the available protocol. Thirdly, if participants withdraw or drop out of the study, the ITT analysis should be performed.

The design of future clinical trials also should be more perfect. Comparison intervention being given a placebo can make sure the clinical effect. The implementation of long-term follow-up is necessary to evaluate prognosis. Clinically relevant outcomes should be reported, such as CFR, IMR, readmission rate, and adverse cardiovascular events. Also, pharmacoeconomics analysis can be applied to optimize the therapeutic schedule.

4.4. Limitations

There were some potential limitations in our systematic review:

1. Just English and Chinese databases were searched because of the language barrier.
2. The methodological quality of these included studies was of low quality.
3. The sample sizes of the present studies were small, which may lead to bias.
4. The longest period of follow-up among the included trials in our research was just 6 months, thus we could not identify the long-term effect of nicorandil on CSX.
5. There was significant statistical heterogeneity for treadmill test results and endothelial function.

We concluded the possible explanations for the apparent heterogeneity were comparison intervention, duration of treatment. Therefore, the results should be interpreted with caution.

5. Conclusions

Nicorandil appears to have some benefit on improving angina symptoms, resting ECG, treadmill test result, ameliorating endothelial dysfunction, and also seems to be relatively safely used in clinical. Due to the low methodological quality of the RCTs, the risk of publication bias, and significant statistical heterogeneity, there is insufficient evidence for the efficacy or safety of nicorandil in the treatment of CSX. The results from this review still need larger, well designed, and high-quality trials to confirm.

Author contributions

Conceptualization: Yuanhui Hu.
Data curation: Guozhen Yuan, Jingjing Shi.
Formal analysis: Qiulei Jia, Guozhen Yuan.
Methodology: Qiulei Jia, Shuqing Shi, Jingjing Shi, Shuai Shi, Yi Wei, Yuanhui Hu.
Visualization: Shuqing Shi, Shuai Shi.
References

[1] Agrawal S, Mehta PK, Bairey Merz CN. Cardiac syndrome X: update. Heart Fail Clin 2016;12:141–36.

[2] Crea F, Lanza GA. Angina pectoris and normal coronary arteries: cardiac syndrome X. Heart (British Cardiac Society) 2004;90:457–63.

[3] Patel MR, Dai D, Hernandez AF, et al. Prevalence and predictors of nonobstructive coronary artery disease identified with coronary angiography in contemporary clinical practice. Am Heart J 2014;167:846–52.e842.

[4] Kanar BG, Sunbul M. Cardiac syndrome X: an important cause of microvascular angina. Turk Kardiylern Dern Ars 2018;46:437–8.

[5] Sera JD, Widmer RJ, Matsuzawa Y, et al. Prevalence of coronary microvascular dysfunction among patients with chest pain and non- obstructive coronary artery disease. JACC Cardiovasc Imaging 2015;8:1445–53.

[6] Kaski JC, Rosano GM, Collins P, et al. Cardiac syndrome X: clinical characteristics and left ventricular function. Long-term follow-up study. J Am Coll Cardiol 1995;25:807–14.

[7] Hirota Y, Ohnaka H, Tsuji R, et al. Excellent prognosis of Japanese patients with chest pain and normal or nearly normal coronary arteries-2- to 13-year follow-up of 274 patients after coronary cineangiography. Jpn Circ J 1994;58:63–8.

[8] Murthy VL, Naya M, Taqueti VR, et al. Effects of sex on coronary microvascular dysfunction and cardiac outcomes. Circulation 2014;129:2518–27.

[9] Murthy VL, Naya M, Foster CR, et al. Association between coronary vascular dysfunction and cardiac mortality in patients with and without diabetes mellitus. Circulation 2012;126:1858–68.

[10] Jepsen L, Hvelplund A, Abildstrom SZ, et al. Stable angina pectoris with no obstructive coronary artery disease is associated with increased risks of major adverse cardiovascular events. Eur Heart J 2012;33:734–44.

[11] Yaşmur J, Aşkçıöz N, Cansel M, et al. Assessment of the left ventricular systolic function in cardiac syndrome X using speckle tracking echocardiography. Anatol J Cardiol 2016;16:419–23.

[12] Xu L, Huang X, Ma J, et al. Value of three-dimensional strain parameters in evaluating myocardial viability. Chin J Cardiovasc Dis J Integr Tradit Chin West Med 2015;24:77.

[13] Cekirdeki EJ, Bugan B. Level of Anxiety and Depression in Cardiac Syndrome X. Med Princ Pract 2019;28:82–6.

[14] Jepsen L, Abildstrom SZ, Hvelplund A, et al. Burden of hospital admission and repeat angiography in angina pectoris patients with and without coronary artery disease: a registry-based cohort study. PloS One 2014;9:e91707.

[15] Kassier GK, Nikoletou D. Cardiac rehabilitation and exercise prescription in symptomatic patients with non-obstructive coronary artery disease-a systematic review. Curr Treat Options Cardiovasc Med 2018;20:78.

[16] Kaski JC, Crea F, Gersh BJ, et al. Reappraisal of ischemic heart disease. Circulation 2018;138:1463–80.

[17] Roffi M, Patrono C, Collet JP, et al. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). Eur Heart J 2016;37:267–315.

[18] Johnston N, Schenck-Gustafsson K, Lagerqvist B. Are we using cardiovascular medications and coronary angiography appropriately in men and women with chest pain? Eur Heart J 2011;32:1331–6.

[19] Russo G, Di Franco A, Lamendola P, et al. Lack of effect of nitrates on exercise stress test results in patients with microvascular angina. Cardiovasc Drugs Ther 2013;27:229–34.

[20] Montalescot G, Sechtem U, Achenbach S, et al. 2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J 2013;34:2949–3003.

[21] Tarkin JM, Kaski JC. Vasodilator therapy: nitrates and nicorandil. Cardiovasc Drugs Ther 2016;30:367–78.

[22] Zhang Y, Chen Y, Fu X, et al. Chinese expert consensus guidelines for diagnosis and management of coronary microvascular disease. Chin Circ J 2017;32:421–30.

[23] Yamabe H, Namura H, Yano T, et al. Effect of nicorandil on abnormal coronary flow reserve assessed by exercise 201Tl scintigraphy in patients with angina pectoris and nearly normal coronary arteriograms. Cardiovasc Drugs Ther 2015;29:755–61.

[24] Chen JW, Lee WL, Hsu NW, et al. Effects of short-term treatment of Nicorandil on exercise-induced myocardial ischemia and abnormal cardiac autonomic function in microvascular angina. Am J Cardiol 1997;80:32–8.

[25] Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ (Clinical research ed) 2009;339:b2535.

[26] Shea B, Hamel C, Wells GA, et al. AMSTAR is a reliable and valid measurement tool to assess the methodological quality of systematic reviews. J Clin Epidemiol 2009;62:1013–20.

[27] Higgins J, Green S. Cochrane handbook for systematic reviews of interventions version 5.1.0. Cochrane Collab. 2011. Available from: http://www.cochranehandbook.org.

[28] Balshem H, Helfand M, Schünemann HJ, et al. GRADE guidelines: 3. Rating the quality of evidence. J Clin Epidemiol 2011;64:401–6.

[29] Oraby MA. Anti-anginal effect of nicorandil versus nitrates in patients with microvascular angina. Eur Heart J 2011;32:572.

[30] Cen Y, Li W, Zhang X, et al. Clinical efficacy of nicorandil in the treatment of microvascular angina and its effect on vascular endothelial function. Hainan Med J 2014;25:807–9.

[31] Chen B, Liu H, Zhang Y, et al. Influence of nicorandil on levels of hsCRP, sCD40L and therapeutic effect of nicorandil in patients with microvascular angina pectoris. Chin J Cardiovasc Rehab Med 2018;27:296–9.

[32] Chen F. Clinical efficacy of nicorandil in the treatment of microvascular angina. J Front Med 2016;6:143–4.

[33] Cui Y. Effect observation of nicorandil in treatment of microvascular angina. China Med Pharmacy 2018;8:250–2.

[34] Gao X, Zhang Q, Zhang W, et al. The effect of nicorandil on stable microvascular angina. Acta Academiae Medicinae Qingdaii Universitatis 2016;322–4.

[35] Han J. The Therapeutic Effects of Nicorandil on Cardiac X Syndrome Patients [Master]. Shandong University; 2012. In press.

[36] He Y. Clinical efficacy of nicorandil in the treatment of microvascular angina and its effect on vascular endothelium. Modern J Integr Tradit Chin West Med 2015;24:2134–5.

[37] He X, Dong J, Zhao Y, et al. Efficacy of nicorandil for treating the patients with cardiac syndrome X and its impact on vascular endothelial function. Chin Circ J 2017;32:676–9.

[38] Hong Y. Efficacy and the incidence of adverse reactions of nicorandil on stable microvascular angina. Strat Pharmaceut J 2019;31:151–2.

[39] Jin G. Clinical efficacy of nicorandil in the treatment of microvascular angina and its effect on vascular endothelial. Contemp Med 2016;131–2.

[40] Jin Z. Comparison of the effect of nicorandil and trimetazidine on microvascular angina. J Med Forum 2016;149–31.

[41] Liu D. The effect of nicorandil on the treatment of microvascular angina pectoris and the improvement of vascular endothelial function. Foreign Med Sci (Section of Medgeography) 2018;39:28–30.

[42] Lv Y, Jia D. Effect of nicorandil on cardiac syndrome X. Chin Heart J 2016;64:5–7.

[43] Quan H, Wang L, Liu X. Analysis of therapeutic effect of nicorandil on stable microvascular angina. Chin J Modern Drug Appl 2018;12:77–9.

[44] Wang D. Comparison of the effect of nicorandil and trimetazidine on microvascular angina. Cardiovasc Dis J Integr Tradit Chin Western Med (Electronic) 2016;4:41–4.

[45] Xu Y. Efficacy of nicorandil for treating the patients with stable microvascular angina. Gansu Sci Technol 2017;33:127–8.

[46] Yan S. Effect observation of nicorandil in treatment of microvascular angina. Modern Dagan Treat 2018;29:3135–6.

[47] Yin K, Deng D, Huang H. Comparison of the effect of nicorandil and trimetazidine in X-syndrome patients. Med Recap 2013;19:4003–5.

[48] Zhang D. Clinical effect, safety and compliance of nicorandil in treatment of microvascular angina. China Licens Pharmacist 2017;14:17–9.

[49] Zhou S. Comparison of therapeutic effect between Nicorandil and isosorbide mononitrate tablets in treatment of microvascular angina. Occupation Health 2012;28:763–4. 766.

[50] He W, Xie Y. Efficacy of nicorandil for treating the patients with microvascular angina. Chin J Clin Rational Drug Use 2019;12:44–5.
Ji Y, Yu X, Wang X, et al. Clinical efficacy of nicorandil in the treatment of microvascular angina. China Pract Med 2020;15:112–5.

Crea F, Camici PG, Bairey Merz CN. Coronary microvascular dysfunction: an update. Eur Heart J 2014;35:1101–11.

Long M, Huang Z, Zhuang X, et al. Association of inflammation and endothelial dysfunction with coronary microvascular resistance in patients with cardiac syndrome X. Arquivos brasileiros de cardiology 2017;109:397–403.

Pepine CJ, Anderson RD, Sharaf BL, et al. Coronary microvascular reactivity to adenosine predicts adverse outcome in women evaluated for suspected ischemia results from the National Heart, Lung and Blood Institute WISE (Women’s Ischemia Syndrome Evaluation) study. J Am Coll Cardiol 2010;55:2825–32.

Pries AR, Reglin B. Coronary microcirculatory pathophysiology: can we afford it to remain a black box? Eur Heart J 2017;38:478–88.

Kostic J, Djordjevic-Dikic A, Dobric M, et al. The effects of nicorandil on microvascular function in patients with ST segment elevation myocardial infarction undergoing primary PCI. Cardiovasc Ultrasound 2015;13:26.

Chen Z, Chen X, Li S, et al. Nicorandil improves myocardial function by regulating plasma nitric oxide and endothelin-1 in coronary slow flow. Coron Artery Dis 2015;26:114–20.

Akai K, Wang Y, Sato K, et al. Vasodilatory effect of nicorandil on coronary arterial microvessels: its dependency on vessel size and the involvement of the ATP-sensitive potassium channels. J Cardiovasc Pharmacol 1995;25:541–7.

Matsubara T, Minatoguchi S, Matsuo H, et al. Three minute, but not one minute, ischemia and nicorandil have a preconditioning effect in patients with coronary artery disease. J Am Coll Cardiol 2000;35:345–51.

Seyedi-Shirvani S, Rasmi Y, Seyyed-Mohammadzad MH, et al. Oxidative stress status in patients with cardiac syndrome X. Scienecasia 2012;38:136.

Demir B, Temizhan A, Keskin G, et al. Comparison of serum gamma-glutamyltransferase levels between patients with cardiac syndrome X and healthy asymptomatic individuals. Kardiol Polska 2012;70:31–7.

Zhang YQ, Tian F, Chen JS, et al. Delayed reendothelialization with rapamycin is rescued by the addition of nicorandil in balloon-injured rat carotid arteries. Oncotarget 2016;7:75926–39.

Colvin HS, Barakat T, Moussa O, et al. Nicorandil associated anal ulcers: an estimate of incidence. Ann R Coll Surg Engl 2012;94:170–2.

Mikkelie-v J, Hghet AS. Nicorandil-induced leg ulceration without mucosal involvement. Clin Exp Dermatol 2014;39:372–3.

Wang JY, Xiao J, Chen J, et al. Potential effectiveness of traditional Chinese medicine for cardiac syndrome X (CSX): a systematic review and meta-analysis. BMC Complement Altern Med 2013;13:62.

Mao HM, Liu M, Qu H, et al. Tongxinluo capsule() for cardiac syndrome X: a systematic review and meta-analysis. Chin J Integr Med 2018;24:296–303.